- Home
- TPVG vs ESPR Comparison
TPVG vs ESPR Comparison
Compare TPVG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- ESPR
- Stock Information
- Founded
- TPVG 2013
- ESPR 2008
- Country
- TPVG United States
- ESPR United States
- Employees
- TPVG N/A
- ESPR N/A
- Industry
- TPVG Other Consumer Services
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- ESPR Health Care
- Exchange
- TPVG Nasdaq
- ESPR Nasdaq
- Market Cap
- TPVG 253.9M
- ESPR 208.1M
- IPO Year
- TPVG N/A
- ESPR 2013
- Fundamental
- Price
- TPVG $7.03
- ESPR $1.15
- Analyst Decision
- TPVG Hold
- ESPR Buy
- Analyst Count
- TPVG 6
- ESPR 6
- Target Price
- TPVG $6.55
- ESPR $6.50
- AVG Volume (30 Days)
- TPVG 248.1K
- ESPR 3.3M
- Earning Date
- TPVG 08-06-2025
- ESPR 08-11-2025
- Dividend Yield
- TPVG 17.14%
- ESPR N/A
- EPS Growth
- TPVG N/A
- ESPR N/A
- EPS
- TPVG 0.93
- ESPR N/A
- Revenue
- TPVG $101,260,000.00
- ESPR $259,574,000.00
- Revenue This Year
- TPVG N/A
- ESPR $4.07
- Revenue Next Year
- TPVG $6.30
- ESPR N/A
- P/E Ratio
- TPVG $7.57
- ESPR N/A
- Revenue Growth
- TPVG N/A
- ESPR 12.99
- 52 Week Low
- TPVG $5.53
- ESPR $0.69
- 52 Week High
- TPVG $9.17
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- TPVG 55.73
- ESPR 59.60
- Support Level
- TPVG $6.93
- ESPR $0.95
- Resistance Level
- TPVG $7.16
- ESPR $1.06
- Average True Range (ATR)
- TPVG 0.17
- ESPR 0.07
- MACD
- TPVG -0.01
- ESPR -0.01
- Stochastic Oscillator
- TPVG 56.33
- ESPR 74.07
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.